241PD BEECH: a randomised phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
Authors
Turner, NAlarcón, E
Armstrong, Anne C
Philco, M
López Chuken, Y
Sablin, M-P
Tamura, K
Gomez Villanueva, A
Pérez-Fidalgo, J
Foxley, A
Lindemann, J
Maudsley, R
Outhwaite, E
Pass, M
Rugman, P
Schiavon, G
Oliveira, M
Affiliation
"Molecular Oncology, The Institute of Cancer Research and The Royal Marsden NHSIssue Date
2017-09
Metadata
Show full item recordCitation
241PD BEECH: a randomised phase 2 study assessing the efficacy of AKT inhibitor AZD5363 combined with paclitaxel in patients with ER+ve advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population. 2017, 28(suppl_5): Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdx365.004Additional Links
http://academic.oup.com/annonc/article/doi/10.1093/annonc/mdx365.004/4108470/241PDBEECH-A-randomised-Phase-2-study-assessingType
Meetings and ProceedingsISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdx365.004